FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

O IVID 7 W	
OMB Number:	3235-0287
Estimated average	hurden

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours per response:	0.5								

Name and Address of Reporting Person* Collins Cynthia					2. Issuer Name and Ticker or Trading Symbol Editas Medicine, Inc. [EDIT]										all app	olicable) ctor	g Person(s) t	o Issuer 6 Owner		
(Last) (First) (Middle) C/O EDITAS MEDICINE, INC. 11 HURLEY ST.					3. Date of Earliest Transaction (Month/Day/Year) 08/06/2019									X	Office below			er (specify ow)		
(Street) CAMBR (City))2141 Zip)		- 4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)									Indiv ne) X	·				
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
1. Title of Security (Instr. 3) 2. Transac Date (Month/Date)					Execution Date,		Transaction Disposed Code (Instr. 5)			rities Acquired (A) d Of (D) (Instr. 3,			4 and Se Be Ov		ount of ties cially I Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	of Indirect			
									Code	v	Amount		(A) or (D)	Price		Reported Transaction(s) (Instr. 3 and 4)			(5 4)	
Common Stock ⁽¹⁾ 08/06.				6/2019				A		8,283	3	A	A \$0 ⁽¹⁾		16,566 ⁽²⁾		D			
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Da if any (Month/Day/Y	Date, Transaction Code (Instr					6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. and 4)		ount		vative urity tr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction((Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership t (Instr. 4)	
	Code V (A) (D)						Date Exercisal	ate Expiration kercisable Date Title			of Sha	res								

Explanation of Responses:

- 1. The common stock received by the Reporting Person was in connection with the grant of a restricted stock unit award to the Reporting Person, for no consideration, and which is scheduled to vest in its entirety on the earlier of (i) the termination of the engagement of the Reporting Person as an interim Chief Executive Officer of Editas Medicine, Inc. and (ii) December 31, 2019.
- 2. Such amount includes common stock to be received by the Reporting Person on or about August 19, 2019 in connection with the anticipated vesting of a Restricted Stock Unit award granted to the Reporting Person and previously reported on Table II of a Form 4 filed by the Reporting Person with the SEC on February 4, 2019.

08/07/2019 /s/ Cynthia Collins

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.